Views 369
Citations 0
Comment & Response
Health Care Reform
October 2014

Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use and Renal Outcomes—Reply

Author Affiliations
  • 1Division of Geriatrics and Gerontology, Institute of Population Health Sciences, National Health Research Institutes, Zhunan, Taiwan
  • 2Department of Health Services Administration, China Medical University and Hospital, Taichung, Taiwan
  • 3Division of Nephrology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan
  • 4Institutes of Physiology and Clinical Medicine, National Yang-Ming University, Taipei, Taiwan

Copyright 2014 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.

JAMA Intern Med. 2014;174(10):1706-1707. doi:10.1001/jamainternmed.2014.1578

In Reply We appreciate the comments of Tomlinson and Smeeth concerning that the differential misclassification would tend to bias our results toward favoring angiotensin-converting enzyme inhibitor or angiotensin receptor blocker (ACEI/ARB) use in patients with predialysis advanced chronic kidney disease, hypertension, and anemia. We performed additional analyses to address the question raised in the letter. However, their speculation is not evidenced by the further analysis from our cohort.

First Page Preview View Large
First page PDF preview
First page PDF preview